BidaskClub lowered shares of TherapeuticsMD (NASDAQ:TXMD) from a buy rating to a hold rating in a research note published on Tuesday morning.
Several other research firms have also weighed in on TXMD. ValuEngine upgraded shares of TherapeuticsMD from a hold rating to a buy rating in a research note on Thursday, February 28th. Zacks Investment Research lowered shares of TherapeuticsMD from a hold rating to a sell rating in a research note on Thursday, February 28th. reiterated a buy rating and issued a $14.00 price objective on shares of TherapeuticsMD in a research note on Tuesday, February 12th. Oppenheimer set a $14.00 price objective on shares of TherapeuticsMD and gave the company a buy rating in a research note on Monday, February 11th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $27.00 price objective on shares of TherapeuticsMD in a research note on Monday, January 21st. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $14.45.
TherapeuticsMD stock opened at $5.44 on Tuesday. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -9.22 and a beta of 2.10. The company has a current ratio of 4.55, a quick ratio of 4.47 and a debt-to-equity ratio of 0.75. TherapeuticsMD has a twelve month low of $3.51 and a twelve month high of $7.66.
In other TherapeuticsMD news, Director Jules A. Musing sold 17,400 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $5.80, for a total value of $100,920.00. Following the completion of the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $29,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.85% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. We Are One Seven LLC bought a new stake in TherapeuticsMD in the fourth quarter worth approximately $26,000. Dfpg Investments Inc. bought a new stake in TherapeuticsMD in the fourth quarter worth approximately $38,000. Weiss Multi Strategy Advisers LLC bought a new stake in TherapeuticsMD in the fourth quarter worth approximately $57,000. Stevens Capital Management LP bought a new stake in TherapeuticsMD in the third quarter worth approximately $101,000. Finally, B. Riley Wealth Management Inc. bought a new stake in TherapeuticsMD in the third quarter worth approximately $102,000. 77.02% of the stock is owned by institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
See Also: Cost of Capital
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.